PCV72 COST-EFFECTIVENESS ANALYSIS OF ADD-ON ALISKIREN TO LOSARTAN TREATMENT FOR PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE CZECH PATIENTS FROM PAYOR PERSPECTIVE
May 1, 2009, 00:00 AM
10.1016/S1098-3015(10)73833-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)73833-X/fulltext
Section Title :
Section Order :
304
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73833-X&doi=10.1016/S1098-3015(10)73833-X